October 05, 2010
Local (JPN)

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126 (Public Relations)
+81-3-6225-1125 (Investor Relations)
http://www.daiichisankyo.com/

Daiichi Sankyo to Launch Percutaneous Analgesic and Anti-Inflammatory Drug Loxonin(R) Gel 1% in Japan

Tokyo, Japan (October 5, 2010) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the launch in Japan of its percutaneous analgesic and anti-inflammatory drug Loxonin® Gel 1% (generic name, loxoprofen sodium hydrate; approval for manufacture and marketing, June 9, 2010; drug price listing, September 24, 2010).

 

Loxonin® Gel 1% contains the same active ingredient, loxoprofen sodium hydrate, as found in pills and powder formulations of the leading oral analgesic and anti-inflammatory Loxonin® brand. The gel offers equivalent efficacy and can be easily applied to an affected area with no displeasing odor.

 

Following the launch of Loxonin® pap in 2006 and Loxonin® tape in 2008, Daiichi Sankyo is confident that this new addition to the Loxonin® lineup, which has been a long-standing top brand since 1986, will further contribute to analgesic and anti-inflammatory drug treatment in Japan.

 

 

Product Outline

 

(Launch date: October 5, 2010)

 Dosage form Percutaneous analgesic and anti-inflammatory drug

 Product name

Loxonin® Gel 1% (generic name: loxoprofen sodium hydrate)

 Drug price

6.8 yen/g (25g package: 170 yen, 50g package: 340 yen)
【Japan standard drug price listing received September 24, 2010】

 Efficacy

Relieves pain and inflammation occurring from the following illnesses and symptoms: degenerative arthritis, muscle pain, swelling and pain caused by external injury

 Dosage

Rub gel on an affected area once per day (appropriate amount dependent on symptoms)

 Remarks

Manufacture and marketing: DAIICHI SANKYO Co., Ltd.

 

End